Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Upadacitinib in Pediatric Crohn's Disease (Japan Cohort of M14-671)
jRCT2071240040Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in Crohn's disease (3 arms), sponsored by AbbVie Inc. Primary endpoints: Clinical remission at Week 64, Endoscopic response at Week 64 and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2071240040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240040.